P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study

Tenosynovial giant cell tumour (TGCT) is a rare, locally aggressive neoplasm caused by upregulation of the colony-stimulating factor 1 (CSF1) gene. Vimseltinib is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1 receptor (CSF1R) and was well tolerated by patients in a phase 1/2 study. Here, we evaluate patient-reported outcome measures for patients with TGCT treated with the recommended phase 2 dose (RP2D) of vimseltinib (30 mg twice weekly; NCT03069469).